NCT01791049

TD-1607 SAD Study in Healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-1607, a Glycopeptide-Cephalosporin Heterodimer Gram-Positive Antibiotic, in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: Theravance Biopharma · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

TD-1607, administered intravenously as single doses, will be investigated in healthy subjects to assess its tolerability, safety, and pharmacokinetics.

Conditions

• Serious Infections Due to Known or Suspected Gram-positive Pathogens

Interventions

Type	Name	Description
DRUG	TD-1607
DRUG	Placebo

Timeline

• Start date: 2013-04-01
• Primary completion: 2013-08-01
• Completion: 2013-10-01
• First posted: 2013-02-13
• Last updated: 2021-01-19

Locations

1 site across 1 country: United States